drugset / Trial / NCT01849640

Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity

NCT01849640

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a two-arm, open label Treatment Study comparing the efficacy, safety, tolerability and pharmacokinetics of a three-day course of Dihydroartemisinin-Piperaquine (DP) with or without single-dose primaquine in patients with uncomplicated Plasmodium falciparum malaria. On the last day of DP therapy, volunteers will be randomized to receive either a single 45 mg dose of primaquine (PQ) or DP treatment only (no primaquine).

Timeline

Start
2012-12
Primary completion
2014-12
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator DHA-piperaquine Unknown 40 mg
Comparator DHA-piperaquine Unknown 320 mg
Comparator Primaquine Small molecule 45 mg